Finance

Lists
ALLO:NASDAQ
Allogene Therapeutics Inc
US$ १.७८
+०.८५%
(+०.०१५) 1D
सेप्टेम्बर ११, ११:५२:१२ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALLO...
Open
US$ १.८०
High
US$ १.८०
Low
US$ १.७५
Mkt. cap
६१.३२ करोड
Avg. vol.
५२.७० लाख
Volume
१२.२० लाख
52-wk high
US$ ४.४६
52-wk low
US$ १.०४
EPS
-US$ ०.६७
Beta
०.४७
Shares outstanding
३४.५५ करोड
No. of employees
१५०
Open
US$ १.८०
High
US$ १.८०
Low
US$ १.७५
Mkt. cap
६१.३२ करोड
Avg. vol.
५२.७० लाख
Volume
१२.२० लाख
52-wk high
US$ ४.४६
52-wk low
US$ १.०४
EPS
-US$ ०.६७
Beta
०.४७
Shares outstanding
३४.५५ करोड
No. of employees
१५०
News stories
From web sources and news partners
About Allogene Therapeutics Inc
CEO-
Employees१५०
Founded२०१७
HeadquartersSouth San Francisco, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 7 analysts giving stock ratings to ALLO in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ALLO in the last 3 months.
Highest
Current US$ १.७८
US$ १४.०० (+६८८.७३%)
Average
US$ १०.२५ (+४७७.४६%)
Lowest
US$ ८.०० (+३५०.७०%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brian Cheng
J.P. Morgan
Hold
Maintained
-
-
08/17/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/12/2026
Unknown Analyst
UBS
Buy
Reiterated
US$ ८.००
+३५०.७%
08/13/2026
Luca Issi
RBC Capital
Buy
Reiterated
US$ ९.००
+४०७%
08/12/2026
Biren Amin
Piper Sandler
Buy
Maintained
US$ १०.००
+४६३.४%
08/13/2026
John Newman
Canaccord Genuity
Buy
Reiterated
US$ १४.००
+६८८.७%
08/13/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
08/13/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
US$ ७.००
+२९४.४%
05/14/2026
Roger Song
Jefferies
Buy
Maintained
US$ १०.००
+४६३.४%
04/15/2026
Jack Allen
Robert W. Baird
Buy
Maintained
US$ ९.००
+४०७%
04/14/2026
William Pickering
Bernstein
Hold
Maintained
US$ ३.८५
+११६.९%
04/14/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ ११.००
+५१९.७%
04/16/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
US$ ८.००
+३५०.७%
04/14/2026
Samantha Semenkow
Citi
Buy
Reiterated
US$ ४.००
+१२५.४%
04/09/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
US$ १०.००
+४६३.४%
03/13/2026
Last report
२०२६ अगस्ट १२
Fiscal period
Q2 2026
EPS / Est. (USD)
-US$ ०.१३ / -US$ ०.१५
+१२.१६%beat
Revenue / Est. (USD)
४६.४० लाख / २.२२ हजार
+२,०८,९०९.०१%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
Revenue
Cost of goods sold
Cost of revenue
Research and development expenses
Total research and development expenses
Selling, general, and admin expenses
Operating expense
Total operating expenses
Operating income
Other non operating income
EBT including unusual items
EBT excluding unusual items
Income tax expense
Effective tax rate
Other operating expenses
Net income
Net profit margin
Earnings per share
Interest and investment income
Interest expense
Net interest expenses
Depreciation and amortization charges
EBITDA
Gain or loss from assets sale
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू